Dhecella Winy Cintya Ningrum

Mrs. Dhecella Winy Cintya Ningrum

Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in Indonesian Journal of Cancer Chemoprevention
Verified
Journal Article
Open access
PDF file
DNDhecella Winy Cintya Ningrum
Dhecella Winy Cintya Ningrum
TKTriana Arum Kusumaningtyas
Triana Arum Kusumaningtyas
RFRifki Febriansah
Rifki Febriansah
MJMelisa Juniananda
Melisa Juniananda
STSri Tasminatun
Sri Tasminatun
AKAnnisa Krisridwany
Annisa Krisridwany
Cervical cancer maintains its second-place ranking for Indonesia's highest number of cancer cases. In 2021, there were 36,633 cases of cervical cancer in Indonesia, with a rising death rate. Commonly, chemotherapy is used to treat cervical cancer and can improve the survival chances of patients, but these therapies imply increased toxicity. Biflavonoid group compounds like amentoflavone and 3,8-Biapigenin have the potential to act as anticancer agents by modulating multiple signaling pathways. This study aims to determine the cervical anticancer potential of amentoflavone and 3,8-Biapigenin based on in silico study. Prediction of anticancer activity in silico using Prediction of Activity Spectra for Active Substances (PASS) online, followed by target protein tracing using STITCH-STRING, then receptor analysis test using Ramachandran plot. A molecular docking test was conducted to determine the binding affinity of the compound with the receptor. Based on the online PASS, the compounds as thought to have low cervical anticancer potential if tested on a laboratory scale. STAT3, EP300, CYP1A1, and AKR1C1 proteins used in this study have met the requirements of a suitable receptor for molecular docking test. The best binding affinity was obtained at the interaction of amentoflavone and STAT3 with a better docking score (-9.3 kcal/mol) than doxorubicin (-7.1 kcal/mol). Overall, the results suggest biflavonoid compounds have the potential to be developed as a chemopreventive agent for cervical cancer.Keywords: bioinformatics, molecular docking, amentoflavone, 3,8-Biapigenin, cervical cancer protein.

11 December 2025 in Marine Drugs
Verified
Journal Article
Open access
PDF file
NHNita Handayani
Nita Handayani
DNDhecella Winy Cintya Ningrum
Dhecella Winy Cintya Ningrum
AHAdha Fauzi Hendrawan
Adha Fauzi Hendrawan
AYAnis Yuniati
Anis Yuniati
RRRaffaele ROMANO
Raffaele ROMANO
Fahrul NurkolisFahrul Nurkolis
Fahrul Nurkolis
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by cholinergic dysfunction, oxidative/nitrosative stress, and neuroinflammation. Marine green algae Caulerpa racemosa are rich in neuroactive lipids and fatty acid derivatives with reported antioxidant and anti-inflammatory properties. However, their integrated mechanistic potential against AD remains largely underexplored. This study aimed to elucidate the neuroprotective mechanisms of C. racemosa metabolites against AD using integrative metabolomics, network pharmacology, molecular docking, and in vitro validation assays. Untargeted LC–HRMS profiling was performed to identify major metabolites in the ethanolic extract of C. racemosa. Neuroprotective targets were predicted via TargetNet, STRING, and Cytoscape (MCODE, CytoNCA). Functional enrichment was conducted using KEGG, GO (BP, MF, CC), and ClueGO. Molecular docking (CB-Dock2) validated compound–target interactions with ACHE, CHRM1, NOS1, and NOS2. Antioxidant (DPPH) and cholinesterase (AChE/BChE) inhibitory activities were evaluated in vitro. Metabolomic profiling identified lipid-dominant metabolites—oleamide, hexadecanamide, palmitoyl ethanolamide, α-linolenic acid, α-eleostearic acid, and 9-oxo-octadecadienoic acid. Network analysis revealed key AD-related hubs (ACHE, CHRM1, NOS1, NOS2) enriched in cholinergic regulation, arachidonic-acid metabolism, oxidative stress response, and nitric oxide signaling. Docking showed moderate multi-target affinities (−6.0 to −8.4 kcal/mol), with α-linolenic acid, α-eleostearic acid, and oxidized C18 lipids exhibiting the strongest interactions—particularly with ACHE and NOS isoforms. In vitro assays showed moderate antioxidant activity (IC50 = 120.97 ± 10.93 µg/mL) and cholinesterase inhibition (AChE IC50 = 136.48 ± 1.70 µg/mL; BChE IC50 = 145.98 ± 3.28 µg/mL), aligning with predicted multi-target interactions. C. racemosa extract exhibits neuroprotective potential through a synergistic combination of cholinergic modulation, antioxidant activity, NOS-mediated nitrosative stress reduction, and suppression of arachidonic-acid inflammatory pathways. These findings support C. racemosa as a promising marine-derived multi-target candidate for AD intervention, warranting further mechanistic and in vivo evaluation.

1 January 2026 in Journal of Applied Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
DNDhecella Winy Cintya Ningrum
Dhecella Winy Cintya Ningrum
RFRifki Febriansah
Rifki Febriansah
MJMelisa Juniananda
Melisa Juniananda
STSri Tasminatun
Sri Tasminatun
AKAnnisa Krisridwany
Annisa Krisridwany
Cervical cancer is a significant health issue in Indonesia, with 36,633 cases reported in 2020. Chemotherapy, especially with doxorubicin, is a primary treatment but causes adverse effects such as cardiotoxicity, hair loss, nausea, vomiting, and immunosuppression. Combining chemotherapy with chemopreventive agents can enhance efficacy and reduce side effects. Selaginella doederleinii, known for its biflavonoid compounds, has potential chemopreventive activity. This study investigated the chemopreventive mechanism of Selaginella doederleinii ethanol extract (EESD) as a co-chemotherapy agent for HeLa cells through in silico and in vitro approaches. High-performance liquid chromatography analysis identified amentoflavone and 2,3-dihydro-3,3-diphenylapigenin as key compounds in EESD. Protein–protein interaction network analysis revealed 24 target receptors associated with cervical cancer, with ESR2 and HSP90AA1 being upregulated and involved in chemical carcinogenesis, estrogen signaling, cancer pathways, and endocrine resistance. EESD exhibited moderate cytotoxic activity (IC50 = 367.89 μg/ml) and demonstrated chemopreventive properties. The mechanism of EESD is presumed to involve the inhibition of key regulatory proteins in cervical cancer, namely ESR2 and HSP90AA1. Furthermore, EESD exhibited a slight synergistic effect with doxorubicin, with a combination index value of 0.85870. This study is the first to explore the chemopreventive potential of EESD along with its underlying mechanism, highlighting its role as a co-chemotherapy agent.

11 July 2023 in Mutiara Medika: Jurnal Kedokteran dan Kesehatan
Verified
Journal Article
Open access
PDF file
DRDevi Rahmawati
Devi Rahmawati
DNDhecella Winy Cintya Ningrum
Dhecella Winy Cintya Ningrum
IKIvana Kinanti Kenyori
Ivana Kinanti Kenyori
RFRifki Febriansah
Rifki Febriansah
MOMelany Ayu Octavia
Melany Ayu Octavia
AHAdi Hermawansyah
Adi Hermawansyah
Cervical cancer results from abnormal cell development in the cervix and is caused by the Human Papillomavirus (HPV). Cancer treatment with chemotherapy drugs has dangerous side effects because it can attack normal cells. Gnetum gnemon L. seeds are known to possess anticancer potential. Therefore, natural ingredients are necessary to develop new cancer drug strategies with minimal side effects. This study aims to determine the anticancer activity of the ethanol fraction of Gnetum gnemon L. Seeds (EFGS) against HeLa cells. The research method used in this study was an identification test to detect compounds from EFGS using the TLC method and the HeLa cell cytotoxic test using the MTT Assay method. The results showed that EFGS contained stilbenoid group compounds based on TLC-Densitometry, with an Rf value of 0.22 cm. The cytotoxic test results on HeLa cells indicated an IC50 value of 784 µg/mL, classifying it as having the potential as a moderate category anticancer agent. Therefore, this study indicates that EFGS can be utilized as a chemopreventive agent.

15 February 2026 in Biointerface Research in Applied Chemistry
Verified
Journal Article
Open access
DNDhecella Winy Cintya Ningrum
Dhecella Winy Cintya Ningrum
NRNabila Fahrida Rahma
Nabila Fahrida Rahma
BMBella Mulyani
Bella Mulyani
LALiony Ariantika
Liony Ariantika
CBCindy Berlianawati
Cindy Berlianawati
RFRifki Febriansah
Rifki Febriansah
Lung cancer is one of the most prevalent types of cancer. Although current treatments such as immunotherapy, targeted therapy, and chemotherapy provide clinical benefits, they are often associated with serious side effects, including drug resistance. Myricetin has demonstrated promising anticancer properties; however, its underlying biological mechanisms and gene interaction networks related to patient survival remain insufficiently explored. This study employs a network pharmacology approach to investigate the interaction network between myricetin and lung cancer–related targets, followed by molecular docking for validation. The analysis revealed 101 nodes and 207 edges within the protein-protein interaction (PPI) network. Centrality analysis identified six key target proteins, and subsequent KEGG pathway enrichment narrowed these to five key proteins, HSP90AA1, CYP19A1, MAPK14, SRC, and AKR1C3, which are involved in seven critical pathways associated with lung cancer progression. Molecular docking demonstrated that myricetin exhibits stronger binding affinities compared to Gefitinib across all targets, with the most favorable binding energy observed with AKR1C3 (-10.6 kcal/mol) and Gefitinib to AKR1C3 (-9.3 kcal/mol). These findings suggest that myricetin exerts multifaceted anticancer effects by modulating key biological processes, including cell proliferation, angiogenesis, inflammation, oxidative stress, and hormonal signaling. Thus, myricetin has the potential to be developed as a therapeutic agent for lung cancer. Therefore, further in vitro analyses are required to evaluate myricetin's anticancer activity in lung cancer cells, along with gene expression studies and safety assessments in normal cells.